Anti-factor H autoantibody-associated hemolytic uremic syndrome: The earlier diagnosed and treated, the better

Kidney International

Volumn 85, Issue 5, 2014, Pages 1019-1022

  Loirat, Chantal ^a,b   Frémeaux Bacchi, Véronique ^c,d  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d CENTRE DE RECHERCHE DES CORDELIERS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; COMPLEMENT COMPONENT C3; COMPLEMENT FACTOR H; COMPLEMENT FACTOR H ANTIBODY; COMPLEMENT FACTOR H RELATED PROTEIN 1; COMPLEMENT FACTOR H RELATED PROTEIN 3; COMPLEMENT FACTOR I; CYCLOPHOSPHAMIDE; ECULIZUMAB; MEMBRANE COFACTOR PROTEIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; UNCLASSIFIED DRUG; CFHR1 PROTEIN, HUMAN; CFHR3 PROTEIN, HUMAN; IMMUNOSUPPRESSIVE AGENT; PLASMA PROTEIN;

ANTIBODY TITER; COMPLEMENT DEFICIENCY; GENE MUTATION; GENETIC POLYMORPHISM; GLOMERULUS FILTRATION RATE; HEMOLYSIS; HEMOLYTIC UREMIC SYNDROME; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; PLASMAPHERESIS; PRIORITY JOURNAL; RELAPSE; REVIEW; SHIGA TOXIN PRODUCING ESCHERICHIA COLI; BLOOD; FEMALE; HEMOLYTIC-UREMIC SYNDROME; IMMUNOLOGY; MALE; TIME TO TREATMENT;

AUTOANTIBODIES; BLOOD PROTEINS; COMPLEMENT C3B INACTIVATOR PROTEINS; FEMALE; HEMOLYTIC-UREMIC SYNDROME; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PLASMA EXCHANGE; TIME-TO-TREATMENT;

EID: 84899721828     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.447     Document Type: Note

References (15)

1. Noris M, Caprioli J, Bresin E et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010; 5: 1844-1859.
2. Fremeaux-Bacchi V, Fakhouri F, Garnier A et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 2013; 8: 554-562.
3. Dragon-Durey MA, Loirat C, Cloarec S et al. Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 2005; 16: 555-563.
4. Dragon-Durey MA, Sethi SK, Bagga A et al. Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol 2010; 21: 2180-2187.
5. Lemaire M, Frémeaux-Bacchi V, Schaefer F et al. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet 2013; 45: 531-536.
6. Moore I, Strain L, Pappworth I et al. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood 2010; 115: 379-387.
7. Jó zsi M, Licht C, Strobel S et al. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood 2008; 111: 1512-1514.
8. Dragon-Durey MA, Blanc C, Marliot F et al. The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome. J Med Genet 2009; 46: 447-450.
9. Holmes LV, Strain L, Staniforth SJ et al. Determining the population frequency of the CFHR3/CFHR1 deletion at 1q32. PLoS One [online] 2013; 8: e60352.
10. Blanc C, Roumenina LT, Ashraf Y et al. Overall neutralization of complement factor H by autoantibodies in the acute phase of the autoimmune form of atypical hemolytic uremic syndrome. J Immunol 2012; 189: 3528-3537.
11. Sinha A, Gulati A, Saini S et al. Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children. Kidney Int 2014; 85: 1151-1160.
12. Pennington H. Escherichia coli O157. Lancet 2010; 376: 1428-1435.
13. Watson R, Lindner S, Bordereau P et al. Standardisation of the factor H autoantibody assay. Immunobiology 2013; 219: 9-16.
14. Sana G, Dragon-Durey MA, Charbit M et al. Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses. Pediatr Nephrol 2013; 29: 75-83.
15. Legendre CM, Licht C, Muus P et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013; 368: 2169-2181